Niacin and related compounds for treating hyperphosphatemia in dialysis patients

Seminars in Dialysis

Volumn 21, Issue 3, 2008, Pages 203-205

  Berns, Jeffrey S ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NICOTINAMIDE; NICOTINIC ACID; SODIUM PHOSPHATE COTRANSPORTER; VITAMIN B COMPLEX;

CHRONIC KIDNEY FAILURE; HUMAN; HYPERPHOSPHATEMIA; PERITONEAL DIALYSIS; REVIEW; TREATMENT OUTCOME;

HUMANS; HYPERPHOSPHATEMIA; KIDNEY FAILURE, CHRONIC; NIACIN; NIACINAMIDE; PERITONEAL DIALYSIS; SODIUM-PHOSPHATE COTRANSPORTER PROTEINS; TREATMENT OUTCOME; VITAMIN B COMPLEX;

EID: 44649159009     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2008.00426.x     Document Type: Review

References (29)

1. Karpe F, Frayn KN : The nicotinic acid receptor - a new mechanism for an old drug. Lancet 363 : 1892 1894, 2004
2. Tunaru S, Kero J, Schaub A, Wufka C, Blaukat A, Pfeffer K, Offermanns S : PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med 9 : 352 355, 2003
3. Guyton JR : Niacin in cardiovascular prevention: mechanisms, efficacy, and safety. Curr Opin Lipidol 18 : 415 420, 2007
4. Chertow GM, Burke SK, Dillon MA, Slatopolsky E : Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients. Nephrol Dial Transplant 14 : 2907 2914, 1999
5. Slatopolsky EA, Burke SK, Dillon MA : RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group. Kidney Int 55 : 299 307, 1999
6. Pieper JA : Understanding niacin formulations. Am J Manag Care 8 (Suppl. 12 S308 S314, 2002
7. Pieper JA : Overview of niacin formulations: differences in pharmacokinetics, efficacy, and safety. Am J Health Syst Pharm 60 (13 Suppl. 2 S9 S14, quiz S25, 2003
8. Menon RM, Adams MH, Gonzalez MA, Tolbert DS, Leu JH, Cefali EA : Plasma and urine pharmacokinetics of niacin and its metabolites from an extended-release niacin formulation. Int J Clin Pharmacol Ther 45 : 448 454, 2007
9. Menon RM, Gonzalez MA, Adams MH, Tolbert DS, Leu JH, Cefali EA : Effect of the rate of niacin administration on the plasma and urine pharmacokinetics of niacin and its metabolites. J Clin Pharmacol 47 : 681 688, 2007
10. Katai K, Tanaka H, Tatsumi S, Fukunaga Y, Genjida K, Morita K, Kuboyama N, Suzuki T, Akiba T, Miyamoto K, Takeda E : Nicotinamide inhibits sodium-dependent phosphate cotransport activity in rat small intestine. Nephrol Dial Transplant 14 : 1195 1201, 1999
11. Kempson SA, McAteer JA, Wu KI, Bacon RA : Nicotinamide and the regulation of renal phosphate transport. Prog Clin Biol Res 258 : 185 193, 1988
12. Wu KI, Bacon RA, Al-Mahrouq HA, Kempson SA : Nicotinamide as a rapid-acting inhibitor of renal brush-border phosphate transport. Am J Physiol 255 (1 Pt 2 F15 F21, 1988
13. Eto N, Tomita M, Hayashi M : NaPi-mediated transcellular permeation is the dominant route in intestinal inorganic phosphate absorption in rats. Drug Metab Pharmacokinet 21 : 217 221, 2006
14. Eto N, Miyata Y, Ohno H, Yamashita T : Nicotinamide prevents the development of hyperphosphataemia by suppressing intestinal sodium-dependent phosphate transporter in rats with adenine-induced renal failure. Nephrol Dial Transplant 20 : 1378 1384, 2005
15. Takahashi Y, Tanaka A, Nakamura T, Fukuwatari T, Shibata K, Shimada N, Ebihara I, Koide H : Nicotinamide suppresses hyperphosphatemia in hemodialysis patients. Kidney Int 65 : 1099 1104, 2004
16. Sampathkumar K, Selvam M, Sooraj YS, Gowthaman S, Ajeshkumar RN : Extended release nicotinic acid - a novel oral agent for phosphate control. Int Urol Nephrol 38 : 171 174, 2006
17. Shimoda K, Akiba T, Matsushima T, Rai T, Abe K, Hoshino M : [Niceritrol decreases serum phosphate levels in chronic hemodialysis patients]. Nippon Jinzo Gakkai Shi 40 : 1 7, 1998
18. Kuboyama N, Watanabe Y, Yamaguchi M, Sato K, Suzuki T, Akiba T : Effects of niceritrol on faecal and urinary phosphate excretion in normal rats. Nephrol Dial Transplant 14 : 610 614, 1999
19. Muller D, Mehling H, Otto B, Bergmann-Lips R, Luft F, Jordan J, Kettritz R : Niacin lowers serum phosphate and increases HDL cholesterol in dialysis patients. Clin J Am Soc Nephrol 2 : 1249 1254, 2007
20. Rottembourg JB, Launay-Vacher V, Massard J : Thrombocytopenia induced by nicotinamide in hemodialysis patients. Kidney Int 68 : 2911 2912, 2005
21. Wakasugi H, Futami T, Muso E, Ono T, Sasayama S, Inui K : Thrombocytopenia and anemia induced by niceritrol used for amelioration of hyperphosphatemia in a hemodialysis patient. Nephron 86 : 97 98, 2000
22. O'Brien T, Silverberg JD, Nguyen TT : Nicotinic acid-induced toxicity associated with cytopenia and decreased levels of thyroxine-binding globulin. Mayo Clin Proc 67 : 465 468, 1992
23. Sampathkumar K, Sooraj YS, Ajeshkumar RP : Extended release nicotinic acid is a promising agent for phosphate control in hemodialysis. Kidney Int 69 : 1281, 2006
24. Guyton JR, Bays HE : Safety considerations with niacin therapy. Am J Cardiol 99 : 22C 31C, 2007
25. Alsheikh-Ali AA, Karas RH : Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system). Am J Cardiol 99 : 379 381, 2007
26. Delanaye P, Weekers L, Krzesinski JM : Diarrhea induced by high doses of nicotinamide in dialysis patients. Kidney Int 69 : 1914, 2006
27. Saika Y, Kodama N, Kimura K, Fujii R, Ohtani H, Mune M, Mimura K, Maeda T, Yukawa S : [Plasma nicotinic acid levels in hemodialysis patients after the administration of niceritrol]. Nippon Jinzo Gakkai Shi 41 : 430 435, 1999
28. Rutkowski B, Slominska E, Szolkiewicz M, Smolenski RT, Striley C, Rutkowski P, et al. : N-methyl-2-pyridone-5-carboxamide: a novel uremic toxin? Kidney Int Suppl 84 : S19 S21, 2003
29. Slominska EM, Smolenski RT, Szolkiewicz M, Leaver N, Rutkowski B, Simmonds HA, et al. : Accumulation of plasma N-methyl-2-pyridone-5-carboxamide in patients with chronic renal failure. Mol Cell Biochem 231 : 83 88, 2002